202 related articles for article (PubMed ID: 30990112)
1. Triple treatment of high-risk prostate cancer. A matched cohort study with up to 19 years follow-up comparing survival outcomes after triple treatment and treatment with hormones and radiotherapy.
Gunnarsson O; Schelin S; Brudin L; Carlsson S; Damber JE
Scand J Urol; 2019; 53(2-3):102-108. PubMed ID: 30990112
[No Abstract] [Full Text] [Related]
2. Combined External Beam Radiation Therapy and Brachytherapy versus Radical Prostatectomy with Adjuvant Radiation Therapy for Gleason 9-10 Prostate Cancer.
Muralidhar V; Mahal BA; Butler S; Lamba N; Yang DD; Leeman J; D'Amico AV; Nguyen PL; Trinh QD; Orio PF; King MT
J Urol; 2019 Nov; 202(5):973-978. PubMed ID: 31144590
[TBL] [Abstract][Full Text] [Related]
3. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
[TBL] [Abstract][Full Text] [Related]
4. A systematic overview of radiation therapy effects in prostate cancer.
Nilsson S; Norlén BJ; Widmark A
Acta Oncol; 2004; 43(4):316-81. PubMed ID: 15303499
[TBL] [Abstract][Full Text] [Related]
5. Stage T3b prostate cancer diagnosed by seminal vesicle biopsy and treated with neoadjuvant hormone therapy, permanent brachytherapy and external beam radiotherapy.
Stone NN; Stock RG
BJU Int; 2019 Feb; 123(2):277-283. PubMed ID: 29956864
[TBL] [Abstract][Full Text] [Related]
6. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
[TBL] [Abstract][Full Text] [Related]
7. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
[TBL] [Abstract][Full Text] [Related]
8. Radical prostatectomy vs radiation therapy and androgen-suppression therapy in high-risk prostate cancer.
Westover K; Chen MH; Moul J; Robertson C; Polascik T; Dosoretz D; Katin M; Salenius S; D'Amico AV
BJU Int; 2012 Oct; 110(8):1116-21. PubMed ID: 22540922
[TBL] [Abstract][Full Text] [Related]
9. Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer.
Kishan AU; Cook RR; Ciezki JP; Ross AE; Pomerantz MM; Nguyen PL; Shaikh T; Tran PT; Sandler KA; Stock RG; Merrick GS; Demanes DJ; Spratt DE; Abu-Isa EI; Wedde TB; Lilleby W; Krauss DJ; Shaw GK; Alam R; Reddy CA; Stephenson AJ; Klein EA; Song DY; Tosoian JJ; Hegde JV; Yoo SM; Fiano R; D'Amico AV; Nickols NG; Aronson WJ; Sadeghi A; Greco S; Deville C; McNutt T; DeWeese TL; Reiter RE; Said JW; Steinberg ML; Horwitz EM; Kupelian PA; King CR
JAMA; 2018 Mar; 319(9):896-905. PubMed ID: 29509865
[TBL] [Abstract][Full Text] [Related]
10. [Comparative study of radical prostatectomy versus external beam radiotherapy (75.6 Gy) combined with hormone therapy for prostate cancer of intermediate D'Amico risk classification].
Boissier R; Karsenty G; Muracciole X; Daniel L; Delaporte V; Maurin C; Coulange C; Lechevallier E
Prog Urol; 2013 Sep; 23(10):861-8. PubMed ID: 24034798
[TBL] [Abstract][Full Text] [Related]
11. Improvement in relapse-free survival throughout the PSA era in patients with localized prostate cancer treated with definitive radiotherapy: year of treatment an independent predictor of outcome.
Kupelian PA; Buchsbaum JC; Elshaikh MA; Reddy CA; Klein EA
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):629-34. PubMed ID: 14529766
[TBL] [Abstract][Full Text] [Related]
12. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
[TBL] [Abstract][Full Text] [Related]
13. Oncological Outcomes After Radical Prostatectomy for High-Risk Prostate Cancer Based on New Gleason Grouping System: A Validation Study From University of Southern California With 3,755 Cases.
Djaladat H; Amini E; Xu W; Cai J; Daneshmand S; Lieskovsky G
Prostate; 2017 May; 77(7):743-748. PubMed ID: 28144967
[TBL] [Abstract][Full Text] [Related]
14. Five-year biochemical recurrence-free and overall survival following high-dose-rate brachytherapy with additional external beam or radical prostatectomy in patients with clinically localized prostate cancer.
Boehm K; Schiffmann J; Tian Z; Lesmana H; Larcher A; Mandel P; Karakiewicz PI; Graefen M; Schwarz R; Krüll A; Tilki D
Urol Oncol; 2016 Mar; 34(3):119.e11-8. PubMed ID: 26602027
[TBL] [Abstract][Full Text] [Related]
15. High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features.
Vargas C; Martínez A; Galalae R; Demanes J; Harsolia A; Schour L; Nuernberg N; Gonzalez J
Prostate Cancer Prostatic Dis; 2006; 9(3):245-53. PubMed ID: 16786040
[TBL] [Abstract][Full Text] [Related]
16. Hormonal therapy or external-beam radiation with brachytherapy and the risk of death from prostate cancer in men with intermediate risk prostate cancer.
Rosenberg JE; Chen MH; Nguyen PL; Braccioforte MH; Moran BJ; D'Amico AV
Clin Genitourin Cancer; 2012 Mar; 10(1):21-5. PubMed ID: 22130293
[TBL] [Abstract][Full Text] [Related]
17. Controversies in prostate cancer radiotherapy: consensus development.
Lukka H; Warde P; Pickles T; Morton G; Brundage M; Souhami L;
Can J Urol; 2001 Aug; 8(4):1314-22. PubMed ID: 11564274
[TBL] [Abstract][Full Text] [Related]
18. [Clinical study of radical prostatectomy for prostate cancer from a single institution].
Ishida R; Kobayashi H; Yoshida S; Ogawa M; Shiota T; Nishikimi T; Yamada H; Yokoi K
Nihon Hinyokika Gakkai Zasshi; 2009 Sep; 100(6):615-24. PubMed ID: 19827538
[TBL] [Abstract][Full Text] [Related]
19. International Multicenter Validation of an Intermediate Risk Subclassification of Prostate Cancer Managed with Radical Treatment without Hormone Therapy.
Berlin A; Moraes FY; Sanmamed N; Glicksman R; Koven A; Espin-Garcia O; Leite ETT; Silva JLF; Gadia R; Nesbitt M; Catton CN; Kaffenberger S; Salami SS; Morgan TM; Hearn JWD; Jackson WC; Mehra R; Chung P; Fleshner NE; Zumsteg ZS; Dess RT; Feng FY; Finelli A; Spratt DE
J Urol; 2019 Feb; 201(2):284-291. PubMed ID: 30153435
[TBL] [Abstract][Full Text] [Related]
20. Differential Risk of Castration Resistance After Initial Radical Prostatectomy or Radiotherapy for Prostate Cancer.
Obata H; Shiota M; Akitake N; Takeuchi A; Kashiwagi E; Dejima T; Kiyoshima K; Inokuchi J; Tatsugami K; Eto M
Anticancer Res; 2017 Oct; 37(10):5631-5637. PubMed ID: 28982880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
